RayKnowChina Research Map
Shortlist0

Not yet recruitingOesophageal squamous cell carcinomaPhase 2

Registered title, quoted from ClinicalTrials.gov

Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2

An open trial on oesophageal squamous cell carcinoma, registered on ClinicalTrials.gov. Led by Tianjin Medical University Cancer Institute & Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07531979, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Histologically confirmed locally advanced or metastatic esophageal squamous cell carcinoma.

    Inclusion criterion 4

  3. No prior systemic therapy for ESCC. Patients who have received neoadjuvant or adjuvant therapy must have experienced disease progression or recurrence more than 6 months after completion of that treatment.

    Inclusion criterion 5

    Patients with metastatic disease must have at least one measurable lesion per RECIST 1.1 criteria; patients with disease after neoadjuvant therapy must have an evaluable lesion.

    Inclusion criterion 6

    Prior treatment with any anti-EGFR monoclonal antibody, or with anti-PD-1/PD-L1 antibody, anti-PD-L2 antibody, anti-CD137 antibody, CTLA-4 antibody, or any other drug/antibody targeting T-cell co-stimulation or checkpoint pathways.

    Exclusion criterion 1

  4. ECOG performance status of 0 or 1, with no deterioration within 7 days.

    Inclusion criterion 3

  5. Hemoglobin (HGB) ≥ 90 g/L.

    Inclusion criterion 8

    Absolute neutrophil count (NEUT) ≥ 1.5 × 10⁹/L.

    Inclusion criterion 9

    Platelet count (PLT) ≥ 80 × 10⁹/L.

    Inclusion criterion 10

    Total bilirubin (TBIL) ≤ 1.5 × the upper limit of normal (ULN).

    Inclusion criterion 11

    Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN; for patients with liver metastases, ALT and AST ≤ 5 × ULN.

    Inclusion criterion 12

    Creatinine clearance ≥ 50 mL/min (calculated by the Cockcroft-Gault formula).

    Inclusion criterion 13

    Activated Partial Thromboplastin Time (APTT) ≤ 1.5 × ULN.

    Inclusion criterion 17

  6. Male or non-pregnant, non-lactating female.

    Inclusion criterion 2

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07531979, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age ≥ 18 years.
  • Male or non-pregnant, non-lactating female.
  • ECOG performance status of 0 or 1, with no deterioration within 7 days.
  • Histologically confirmed locally advanced or metastatic esophageal squamous cell carcinoma.
  • No prior systemic therapy for ESCC. Patients who have received neoadjuvant or adjuvant therapy must have experienced disease progression or recurrence more than 6 months after completion of that treatment.
  • Patients with metastatic disease must have at least one measurable lesion per RECIST 1.1 criteria; patients with disease after neoadjuvant therapy must have an evaluable lesion.
  • Adequate organ and bone marrow function, as demonstrated by the following laboratory values:
  • Hemoglobin (HGB) ≥ 90 g/L.
  • Absolute neutrophil count (NEUT) ≥ 1.5 × 10⁹/L.
  • Platelet count (PLT) ≥ 80 × 10⁹/L.
  • Total bilirubin (TBIL) ≤ 1.5 × the upper limit of normal (ULN).
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN; for patients with liver metastases, ALT and AST ≤ 5 × ULN.
  • Creatinine clearance ≥ 50 mL/min (calculated by the Cockcroft-Gault formula).
  • Urine protein < (++) or 24-hour urinary protein < 1.0 g.
  • Normal coagulation function and no active bleeding:
  • International Normalized Ratio (INR) ≤ 1.5.
  • Activated Partial Thromboplastin Time (APTT) ≤ 1.5 × ULN.
  • For women of childbearing potential: negative pregnancy test (serum or urine) within 14 days prior to enrollment, and agreement to use adequate contraception during the study period and for 8 weeks after the last dose of study drug. For men: surgically sterile or agreement to use adequate contraception during the study period and for 8 weeks after the last dose of study drug.
  • Expected survival ≥ 6 months.
  • Patient voluntarily participates in the study and signs the informed consent form (ICF).
  • Patient is expected to be compliant and able to undergo follow-up for efficacy and adverse events as required by the protocol.

Exclusion Criteria:

Patients meeting any of the following criteria at screening will be excluded from the study:

  • Prior treatment with any anti-EGFR monoclonal antibody, or with anti-PD-1/PD-L1 antibody, anti-PD-L2 antibody, anti-CD137 antibody, CTLA-4 antibody, or any other drug/antibody targeting T-cell co-stimulation or checkpoint pathways.
  • Administration of a live vaccine within 4 weeks prior to enrollment or anticipated during the study period.
  • Active autoimmune disease or a history of autoimmune disease within 4 weeks prior to enrollment.
  • Prior allogeneic bone marrow transplantation or solid organ transplant.
  • Uncontrolled hypertension at enrollment, defined as: systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 90 mmHg.
  • Any disease or condition affecting drug absorption at enrollment.
  • Clinically significant cardiovascular disease, including but not limited to: acute myocardial infarction within 6 months prior to enrollment; severe/unstable angina or coronary artery bypass grafting; congestive heart failure > New York Heart Association (NYHA) Class 2; ventricular arrhythmias requiring medication; left ventricular ejection fraction (LVEF) < 50%.
  • Active or uncontrolled severe infection (≥ CTCAE v5.0 Grade 2 infection).
  • Known HIV infection. Known clinically significant liver disease, including viral hepatitis [known hepatitis B virus (HBV) carriers must be excluded if they have active HBV infection, i.e., HBV DNA positive (>1×10⁴ copies/mL or >2000 IU/mL); known hepatitis C virus (HCV) infection with HCV RNA positive (>1×10³ copies/mL)].
  • Any other disease, clinically significant metabolic abnormality, physical examination finding, or laboratory abnormality that, in the investigator's judgment, reasonably suggests the presence of a disease or condition that contraindicates the use of the investigational drug (e.g., a condition associated with seizures requiring treatment), would affect the interpretation of study results, or would place the patient at high risk.
  • Patients deemed by the investigator to be unsuitable for participation in this study.

Quoted from ClinicalTrials.gov, NCT07531979, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07531979, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07531979